| Recruiting | A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft F Delayed Graft Function, End Stage Renal Disease, Deceased Donor Kidney Transplant | Phase 3 | 2026-02-01 |
| Not Yet Recruiting | A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis FSGS | Phase 2 / Phase 3 | 2025-12-01 |
| Completed | Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 3 | 2025-10-24 |
| Recruiting | A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerab Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 2 | 2025-06-23 |
| Active Not Recruiting | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerabilit Geographic Atrophy | — | 2023-09-28 |
| Active Not Recruiting | An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Peg C3G, IC-MPGN, C3 Glomerulopathy | Phase 3 | 2023-05-29 |
| Completed | Geographic Atrophy Long-Terms Outcomes Study Geographic Atrophy | — | 2022-09-01 |
| Completed | Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immun C3G, IC-MPGN, C3 Glomerulopathy | Phase 3 | 2021-11-12 |
| Active Not Recruiting | Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN C3G, IC-MPGN, Renal Transplant | Phase 2 | 2021-09-07 |
| Completed | An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geo Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 3 | 2021-03-04 |
| Recruiting | A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria | Phase 2 | 2021-02-04 |
| Terminated | MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Scle Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 2 | 2020-09-30 |
| Completed | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 COVID, Covid-19, Coronavirus | Phase 1 / Phase 2 | 2020-05-28 |
| Completed | A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | 2019-08-27 |
| Completed | Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy Geographic Atrophy | Phase 1 | 2018-11-05 |
| Completed | A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy | Phase 3 | 2018-08-31 |
| Completed | Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With G Geographic Atrophy | Phase 3 | 2018-08-31 |
| Active Not Recruiting | Pegcetacoplan Long Term Safety and Efficacy Extension Study PNH | Phase 3 | 2018-08-27 |
| Completed | A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetac PNH | Phase 2 | 2018-08-16 |
| Completed | Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | 2018-06-14 |
| Completed | Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy | Phase 2 | 2018-02-26 |
| Terminated | Pegcetacoplan (APL-2) in Neovascular AMD Neovascular Age-related Macular Degeneration | Phase 1 / Phase 2 | 2018-02-14 |
| Completed | Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemol Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease | Phase 2 | 2017-08-31 |
| Completed | Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH S Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | 2015-12-01 |
| Completed | Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy Geographic Atrophy | Phase 2 | 2015-09-24 |
| Completed | A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects Wit Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 1 | 2015-02-23 |
| Completed | Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients Wit Neovascular Age-Related Macular Degeneration | Phase 1 | 2015-01-28 |
| Approved For Marketing | C3G/Primary IC-MPGN EAP C3G, IC-MPGN, C3 Glomerulopathy | — | — |